GlassScriptPhysician profile
Anwarul Haq
NPI 1568480689
$5,513.33
in general payments reported to CMS, 2019-2025
14 companies · $21.92 in 2025
The $21.92 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,835 · 2020: $175 · 2021: $370 · 2022: $14.32 · 2023: $73.63 · 2024: $23.50 · 2025: $21.92.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $119.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $119.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $4,586.61 | 2019 | |
| Abbvie INC. | $248.50 | 2021-2023 | |
| Ucb, INC. | $227.39 | 2019-2020 | |
| Biohaven Pharmaceuticals, INC. | $145.74 | 2021 | |
| Novartis Pharmaceuticals Corporation | $66.87 | 2020-2021 | |
| Boston Scientific Corporation | $56.16 | 2023-2024 | Varithena Administration Pack |
| Sunovion Pharmaceuticals INC. | $28.69 | 2019 | |
| Allergan, INC. | $25.10 | 2020 | |
| Amgen INC. | $24.06 | 2020 | |
| Eisai INC. | $23.89 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $23.73 | 2020 | |
| Argenx US, INC. | $21.92 | 2025 | Vyvgart Hytrulo |
| Janssen Pharmaceuticals, INC | $18.73 | 2019 | |
| Greenwich Biosciences, INC. | $15.94 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anwarul Haq listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.